Initial Statement of Beneficial Ownership (3)
November 21 2016 - 1:10PM
Edgar (US Regulatory)
FORM 3
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0104
Estimated average burden
hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
Meyers James R
|
2. Date of Event Requiring Statement (MM/DD/YYYY)
11/10/2016
|
3. Issuer Name
and
Ticker or Trading Symbol
GILEAD SCIENCES INC [GILD]
|
(Last)
(First)
(Middle)
GILEAD SCIENCES, INC., 333 LAKESIDE DRIVE
|
4. Relationship of Reporting Person(s) to Issuer (Check all applicable)
_____ Director
_____ 10% Owner
___
X
___ Officer (give title below)
_____ Other (specify below)
EVP Worldwide Commercial Ops /
|
(Street)
FOSTER CITY, CA 94404
(City)
(State)
(Zip)
|
5. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_
X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Beneficially Owned
|
1.Title of Security
(Instr. 4)
|
2. Amount of Securities Beneficially Owned
(Instr. 4)
|
3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)
|
4. Nature of Indirect Beneficial Ownership
(Instr. 5)
|
Common Stock
|
6726
|
D
|
|
Common Stock
|
121151
|
I
|
By Trust
|
Table II - Derivative Securities Beneficially Owned (
e.g.
, puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security
(Instr. 4)
|
2. Date Exercisable and Expiration Date
(MM/DD/YYYY)
|
3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)
|
4. Conversion or Exercise Price of Derivative Security
|
5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)
|
6. Nature of Indirect Beneficial Ownership
(Instr. 5)
|
Date Exercisable
|
Expiration Date
|
Title
|
Amount or Number of Shares
|
Non-qualified Stock Option (Right to Buy)
|
(3)
|
10/22/2017
|
Common Stock
|
60000
|
$21.00
|
D
|
|
Non-qualified Stock Option (Right to Buy)
|
(3)
|
1/30/2018
|
Common Stock
|
100000
|
$21.575
|
D
|
|
Non-qualified Stock Option (Right to Buy)
|
(3)
|
1/21/2019
|
Common Stock
|
60000
|
$23.60
|
D
|
|
Non-qualified Stock Option (Right to Buy)
|
(3)
|
7/29/2019
|
Common Stock
|
60000
|
$24.905
|
D
|
|
Non-qualified Stock Option (Right to Buy)
|
(3)
|
1/28/2020
|
Common Stock
|
53200
|
$23.755
|
D
|
|
Non-qualified Stock Option (Right to Buy)
|
(4)
|
1/20/2021
|
Common Stock
|
67200
|
$19.085
|
D
|
|
Non-qualified Stock Option (Right to Buy)
|
(4)
|
1/26/2022
|
Common Stock
|
48000
|
$24.295
|
D
|
|
Non-qualified Stock Option (Right to Buy)
|
(4)
|
2/1/2023
|
Common Stock
|
34890
|
$40.56
|
D
|
|
Non-qualified Stock Option (Right to Buy)
|
(4)
|
2/1/2024
|
Common Stock
|
25780
|
$80.65
|
D
|
|
Non-qualified Stock Option (Right to Buy)
|
(4)
|
2/1/2025
|
Common Stock
|
17590
|
$104.83
|
D
|
|
Non-qualified Stock Option (Right to Buy)
|
(4)
|
2/1/2026
|
Common Stock
|
17560
|
$84.05
|
D
|
|
Non-qualified Stock Option (Right to Buy)
|
(4)
|
8/10/2026
|
Common Stock
|
15450
|
$78.90
|
D
|
|
Restricted Stock Unit
|
(2)
|
(2)
|
Common Stock
|
9780
|
(1)
|
D
|
|
Explanation of Responses:
|
(
1)
|
Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.
|
(
2)
|
The restricted stock units have a four year vesting schedule. 25% vest on the anniversary of the date of grant until fully vested.
|
(
3)
|
The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested.
|
(
4)
|
The options have a four year vesting schedule. 25% of the options will vest on the first anniversary date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.
|
Reporting Owners
|
Reporting Owner Name / Address
|
Relationships
|
Director
|
10% Owner
|
Officer
|
Other
|
Meyers James R
GILEAD SCIENCES, INC.
333 LAKESIDE DRIVE
FOSTER CITY, CA 94404
|
|
|
EVP Worldwide Commercial Ops
|
|
Signatures
|
/s/ Marissa Song by Power of Attorney for James R. Meyers
|
|
11/21/2016
|
**
Signature of Reporting Person
|
Date
|
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
|
*
|
If the form is filed by more than one reporting person,
see
Instruction 5(b)(v).
|
**
|
Intentional misstatements or omissions of facts constitute Federal Criminal Violations.
See
18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
|
Note:
|
File three copies of this Form, one of which must be manually signed. If space is insufficient,
see
Instruction 6 for procedure.
|
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
|
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Sep 2024 to Oct 2024
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Oct 2023 to Oct 2024